Apellis Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 41 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 34.15.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Apellis Pharmaceuticals Inc is 8.87, ranking 32 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 458.58M, representing a year-over-year increase of 132.98%, while its net profit experienced a year-over-year increase of 475.52%.
Key Metrics
The current valuation score of Apellis Pharmaceuticals Inc is 7.55, ranking 65 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 66.26, which is 16.22% below the recent high of 77.01 and 132.72% above the recent low of -21.68.
The current earnings forecast score of Apellis Pharmaceuticals Inc is 7.74, ranking 97 out of 159 in the Pharmaceuticals industry. The average price target is 36.00, with a high of 55.00 and a low of 19.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Apellis Pharmaceuticals Inc is 6.96, ranking 94 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 27.55 and the support level at 19.35, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Apellis Pharmaceuticals Inc is 10.00, ranking 1 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 116.63%, representing a quarter-over-quarter decrease of 1.58%. The largest institutional shareholder is The Vanguard, holding a total of 10.66M shares, representing 8.42% of shares outstanding, with 4.68% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Apellis Pharmaceuticals Inc is 4.55, ranking 88 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Apellis Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
